Wedbush analyst David Nierengarten joins BiotechTV for Analyst Thursdays from San Francisco

blonca9
Feb 15, 2024
1 min read

Updated: Feb 16, 2024

David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, Sutro Biopharma, Scholar Rock, and more.

Recent Posts

See All

Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more

Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross

William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago

Wedbush analyst David Nierengarten joins BiotechTV for Analyst Thursdays from San Francisco

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight